No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Merck & Co beat market forecasts with its first-quarter results on Thursday and raised its full-year guidance on the back of strong growth for Keytruda, its flagship humanised monoclonal antibody (PD-1 inhibitor) used to treat 18 types of cancer.
Group revenues rose 5% to $16.29bn, well ahead of the $15.85bn consensus forecast, with Keytruda sales rising 12% over last year to $8.0bn.
Results were also given a boost by sales of Merck's pulmonary arterial hypertension treatment Winrevair, which jumped 88% to $525m, and 13% sales growth from the animal health division.
The firm swung to a loss of $4.24bn, from a $5.08bn profit previously, due to a significant charge related to last year's Cidara Therapeutics acquisition. However, the adjusted loss of $1.28 a share came in above the $1.47 per-share loss expected by the market.
Looking ahead, Merck narrowed and slightly raised the midpoint of its sales guidance to $65.8bn-67.0bn, up from $65.5bn-67.0bn previously.
Despite the Q1 beat, shares were swinging between gains and losses in morning trade on Wall Street, and were down 0.4% at $110.52 by 1620 BST.
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.